TY - JOUR
T1 - Diagnosis and treatment of anaphylactic reactions to Hymenoptera stings in children
AU - Chipps, Bradley E.
AU - Valentine, Martin D.
AU - Kagey-Sobotka, Anne
AU - Schuberth, Kenneth C.
AU - Lichtenstein, Lawrence M.
N1 - Funding Information:
From the Departments of Pediatrics and Medicine, The Johns Hopkins School of Medicine at The Good Samaritan Hospital, Supported by AI 08270 and AI 07007, National Institutes of Health Training Grants, and The Hospital for Consumptives of Maryland (Eudowood). *Reprint address: Good Samaritan Hospital, 5601 Loch Raven Blvd., Baltimore. MD 21239.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1980/8
Y1 - 1980/8
N2 - Forty-four children (mean age 9.6 years) with a history of an allergic reaction(s) to an insect sting and with positive insect venom skin tests were studied. IgE antibodies (RAST) to honeybee phospholipase A and to yellow jacket venom were found in the sera of 78% and 77%, respectively, of these patients. The patients were immunized with the appropriate venoms over a 15-week course and most were then subjected to an in-hospital sting; there was a 3% reaction rate (1/37). Clinical protection was associated with a fivefold increase in anti-venom IgG. Five patients did not develop a significant increase in IgG antibody and they were treated more vigorously; four were stung subsequently without reaction. Two patients dit not react when stung in the field; positive identification of the culprit insect was obtained. Twenty patients were re-stung after one year of maintenance therapy; there was a single mild, delayed reaction. Immunotherapy also increased the IgE antibody against venom 3.7-fold at three months; after one year of therapy the IgE antibody level had decreased but was still 40% greater than at the outset. Immunotherapy was associated with a 25% incidence of local pain and swelling and a 6% incidence of systemic reactions. We conclude that venom therapy in children is safe and effective. The indications for initiating immunotherapy require further definition.
AB - Forty-four children (mean age 9.6 years) with a history of an allergic reaction(s) to an insect sting and with positive insect venom skin tests were studied. IgE antibodies (RAST) to honeybee phospholipase A and to yellow jacket venom were found in the sera of 78% and 77%, respectively, of these patients. The patients were immunized with the appropriate venoms over a 15-week course and most were then subjected to an in-hospital sting; there was a 3% reaction rate (1/37). Clinical protection was associated with a fivefold increase in anti-venom IgG. Five patients did not develop a significant increase in IgG antibody and they were treated more vigorously; four were stung subsequently without reaction. Two patients dit not react when stung in the field; positive identification of the culprit insect was obtained. Twenty patients were re-stung after one year of maintenance therapy; there was a single mild, delayed reaction. Immunotherapy also increased the IgE antibody against venom 3.7-fold at three months; after one year of therapy the IgE antibody level had decreased but was still 40% greater than at the outset. Immunotherapy was associated with a 25% incidence of local pain and swelling and a 6% incidence of systemic reactions. We conclude that venom therapy in children is safe and effective. The indications for initiating immunotherapy require further definition.
UR - http://www.scopus.com/inward/record.url?scp=0018850931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018850931&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(80)80470-7
DO - 10.1016/S0022-3476(80)80470-7
M3 - Article
C2 - 7400882
AN - SCOPUS:0018850931
SN - 0022-3476
VL - 97
SP - 177
EP - 184
JO - The Journal of pediatrics
JF - The Journal of pediatrics
IS - 2
ER -